Business Description
Ipca Laboratories Ltd
ISIN : INE571A01038
Compare
Compare
Traded in other countries / regions
524494.India IPO Date
1994-05-06Description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | 0.8 | |||||
| Interest Coverage | 10.15 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 8.71 | |||||
| Beneish M-Score | -2.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.3 | |||||
| 3-Year EBITDA Growth Rate | -6 | |||||
| 3-Year EPS without NRI Growth Rate | -17.1 | |||||
| 3-Year FCF Growth Rate | -9.9 | |||||
| 3-Year Book Growth Rate | 10.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 31.24 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.48 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.77 | |||||
| 9-Day RSI | 58.1 | |||||
| 14-Day RSI | 55.48 | |||||
| 6-1 Month Momentum % | 41.36 | |||||
| 12-1 Month Momentum % | 50.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 1.32 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 308.49 | |||||
| Days Sales Outstanding | 75.73 | |||||
| Days Payable | 102.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.25 | |||||
| Dividend Payout Ratio | 0.15 | |||||
| 3-Year Dividend Growth Rate | -20.6 | |||||
| Forward Dividend Yield % | 0.25 | |||||
| 5-Year Yield-on-Cost % | 0.7 | |||||
| Shareholder Yield % | 1.29 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.27 | |||||
| Operating Margin % | 13.02 | |||||
| Net Margin % | 7.82 | |||||
| FCF Margin % | 6.31 | |||||
| ROE % | 10.34 | |||||
| ROA % | 5.85 | |||||
| ROIC % | 7.88 | |||||
| ROC (Joel Greenblatt) % | 14.24 | |||||
| ROCE % | 12.57 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 60.71 | |||||
| Forward PE Ratio | 34 | |||||
| PE Ratio without NRI | 57.87 | |||||
| Shiller PE Ratio | 23.73 | |||||
| Price-to-Owner-Earnings | 74.48 | |||||
| PEG Ratio | 6.5 | |||||
| PS Ratio | 4.75 | |||||
| PB Ratio | 5.99 | |||||
| Price-to-Tangible-Book | 6.21 | |||||
| Price-to-Free-Cash-Flow | 75.26 | |||||
| Price-to-Operating-Cash-Flow | 42.49 | |||||
| EV-to-EBIT | 36.5 | |||||
| EV-to-EBITDA | 26.88 | |||||
| EV-to-Revenue | 4.79 | |||||
| EV-to-FCF | 75.91 | |||||
| Price-to-Projected-FCF | 3.69 | |||||
| Price-to-Graham-Number | 3.99 | |||||
| Price-to-Net-Current-Asset-Value | 41.94 | |||||
| Earnings Yield (Greenblatt) % | 2.74 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 9.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipca Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 84,507.7 | ||
| EPS (TTM) (₹) | 26.06 | ||
| Beta | 0.57 | ||
| Volatility % | 25.63 | ||
| 14-Day RSI | 55.48 | ||
| 14-Day ATR (₹) | 48.156883 | ||
| 20-Day SMA (₹) | 1541.5675 | ||
| 12-1 Month Momentum % | 50.02 | ||
| 52-Week Range (₹) | 1053.45 - 1708.7 | ||
| Shares Outstanding (Mil) | 253.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipca Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipca Laboratories Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ipca Laboratories Ltd Frequently Asked Questions
What is Ipca Laboratories Ltd(BOM:524494)'s stock price today?
The current price of BOM:524494 is ₹1582.25. The 52 week high of BOM:524494 is ₹1708.70 and 52 week low is ₹1053.45.
When is next earnings date of Ipca Laboratories Ltd(BOM:524494)?
The next earnings date of Ipca Laboratories Ltd(BOM:524494) is 2025-02-14 Est..
Does Ipca Laboratories Ltd(BOM:524494) pay dividends? If so, how much?
The Dividend Yield %  of Ipca Laboratories Ltd(BOM:524494) is 0.25% (As of Today), Highest Dividend Payout Ratio of Ipca Laboratories Ltd(BOM:524494) was 0.22. The lowest was 0.03. And the median was 0.12. The  Forward Dividend Yield % of Ipca Laboratories Ltd(BOM:524494) is 0.25%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers